GlassScriptPhysician profile
Avigail Itzkowitz
NPI 1760094437
$1,110.20
in general payments reported to CMS, 2019-2025
11 companies · $937 in 2025
The $937 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $173 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.20 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $209.76 | 2025 | Voquezna |
| Vivus LLC | $170.41 | 2024-2025 | Qsymia, Pancreaze |
| Janssen Biotech, INC. | $154.82 | 2025 | Tremfya |
| Genzyme Corporation | $124.75 | 2024-2025 | |
| Abbvie INC. | $114.72 | 2024-2025 | |
| Pfizer INC. | $92.58 | 2024-2025 | |
| Madrigal Pharmaceuticals | $83.64 | 2025 | Rezdiffra |
| Ardelyx, INC. | $73.24 | 2024-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $42.42 | 2024-2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $22.40 | 2025 | Eohilia |
| Novo Nordisk INC | $21.46 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avigail Itzkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.